Alcon Inc. (ALC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: positive revenue growth and product launches are offset by flat operating margins and tariff pressures. The Q&A highlights optimism in product growth, but challenges in margins and competitive pressures remain. The market strategy appears sound, but financial health concerns persist due to flat free cash flow and margin pressures. Shareholder returns are stable, with no significant changes. Overall, the sentiment is neutral, as positive elements are balanced by ongoing challenges and uncertainties.
Key Financial Performance
First Quarter Sales $2.7 billion, up 6% year-over-year. Growth driven by product innovation, price increases, and strong performance in dry eye portfolio and surgical equipment.
Surgical Franchise Revenue $1.5 billion, up 6% year-over-year. Growth supported by strong momentum from Unity equipment and solid performance in U.S. IOLs.
Implantable Sales $438 million, up 1% year-over-year. Growth in U.S. IOLs offset by competitive pressures internationally and pressure in surgical glaucoma.
Consumables Sales $769 million, up 4% year-over-year. Growth reflects softer market conditions and price increases.
Equipment Sales $253 million, up 23% year-over-year. Growth driven by strong momentum from Unity platform.
Vision Care Sales $1.2 billion, up 6% year-over-year. Growth driven by product innovation, price increases, and strong performance in dry eye portfolio.
Contact Lens Sales $738 million, up 4% year-over-year. Growth driven by product innovation and price increases, partially offset by declines in legacy products.
Ocular Health Sales $487 million, up 10% year-over-year. Growth led by dry eye portfolio, including Tryptyr and Systane.
Core Gross Margin 63%, down 40 basis points year-over-year. Decline due to 120 basis points of pressure from incremental tariffs.
Core Operating Margin 21.2%, flat year-over-year. Improved operating leverage offset by tariff pressure and investments in product launches and R&D.
Core Diluted Earnings Per Share $0.85 per share, reflecting steady performance.
Free Cash Flow $279 million, flat year-over-year. Stable cash flow generation.
Tariff-Related Charges $33 million in the first quarter, recognized in cost of sales.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Unity Phaco-Vit device: Unity platform represents a significant equipment upgrade opportunity, enhancing surgeon control, improving efficiency, and streamlining surgical workflow. Unity VCS was named an Edison Award winner and has been introduced across major markets worldwide. Unity CS, a stand-alone cataract system, increases surgical throughput while maintaining precision and safety.
PanOptix Pro: Latest trifocal IOL with features reducing light scatter and delivering greater quality of vision. It has driven growth in the PC-IOL category and is being launched in international markets like Australia, Japan, South Korea, and Europe.
TruPlus: Enhanced monofocal IOL extending the range of vision without compromising distance performance. It includes a toric version for astigmatism correction.
Valeda: Photobiomodulation device for intermediate dry AMD, offering a noninvasive treatment option. Reimbursement is progressing, and physician education is expanding.
TOTAL 30: Monthly lens with water gradient technology for exceptional comfort. Expanded to include sphere, toric, and multifocal modalities, including a multifocal toric contact lens.
PRECISION 7: 1-week replacement lens offering a comfortable experience at an attractive price point.
Systane Pro: Advanced artificial tear with a triple-action formula for long-lasting relief, contributing to share gains in the U.S. artificial tears market.
Tryptyr: Dry eye pharmaceutical product with rapid onset and novel mechanism of action, capturing market share and expanding coverage.
Market share gains: Gains in U.S. AT-IOLs, surgical equipment, consumables, contact lenses, and dry eye categories.
Global AT-IOL penetration: Increased by 130 basis points to approximately 17%, with stronger growth excluding China.
AI integration: AI is being used to enhance productivity, quality, and speed across R&D, operations, quality, and commercial analytics.
Share repurchase program: A new $1.5 billion share repurchase program approved to be executed over the next 3 years, reflecting strong cash flow and balance sheet.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Uneven market conditions, particularly in cataract surgery, with global procedure volumes growing only in low single digits. Persistent softness in the market could impact growth.
Tariffs: Incremental tariffs have pressured core gross margins, with $33 million of tariff-related charges in Q1 and an average tariff rate of approximately 10% on U.S. imports expected to persist.
Competitive Pressures: Ongoing competitive pressures internationally, particularly in implantables and surgical glaucoma, have impacted growth.
China Market Weakness: Weakness in the Chinese market has pressured global AT-IOL penetration growth, which was otherwise strong in most regions.
Supply Chain and Operational Challenges: Managing operating room installations and ensuring quality, service, and support for customers remain critical as the company scales innovation and expands its installed base.
Regulatory and Reimbursement Challenges: Reimbursement for new products like Valeda is still progressing, with one Medicare administrative contractor yet to provide coverage. Expanding private payer engagement is ongoing.
Economic Uncertainty: Global economic uncertainties and mixed market conditions could impact the company's ability to achieve historical growth levels in certain segments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects constant currency sales growth of between 5% and 7% for 2026.
Operating Margin: Core operating margin expansion is expected to be between 70 and 170 basis points, with most of the expansion occurring in the second half of the year.
Earnings Per Share (EPS): Core diluted EPS growth is projected to be between 10% and 13% for 2026.
Market Growth Assumptions: Aggregate eye care markets are expected to grow 3% to 4% for the year.
Tariff Impact: The company assumes an average tariff rate of approximately 10% on U.S. imports for the remainder of the year, resulting in an estimated $25 million reduction in tariff expense compared to previous guidance.
Product Launches: Upcoming launches include an upgraded version of Vivity IOL in early 2027, Unity M microscope, Unity DX diagnostic device, and a new entry into the eye whitening category.
Innovation Pipeline: The company emphasizes a strong innovation pipeline with advancements in AI to enhance productivity, quality, and speed across R&D, operations, and commercial activities.
Market Trends: Global AT-IOL penetration increased by 130 basis points to approximately 17%, with stronger growth excluding China. Cataract surgery volumes are expected to grow at low single digits, with market growth anticipated to return to historical levels over time.
Share Repurchase Program: The Board approved a $1.5 billion share repurchase program to be executed over the next 3 years.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Approval: At the Annual General Meeting, shareholders approved a dividend of CHF 0.28 per share, expected to be paid on or around May 7.
Share Repurchase Program: The Board approved a new $1.5 billion share repurchase program to be executed over the next 3 years. This program reflects the company's strong balance sheet and robust cash flow generation, aligning with capital allocation priorities.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What factors contributed to the 1% growth in the implantable category, and how is the company addressing challenges in this area?
A:The 1% growth in implantables was influenced by changes in glaucoma implantable reimbursement, a $3-4 million supply issue with Hydrus, and inventory adjustments in China due to VBP. Excluding these factors, core growth was about 3%, with the U.S. showing 6% growth. The company is optimistic about PanOptix Pro and other new products like TruPlus and Vivity Pro to drive future growth.
Q:Why did gross margins come in higher than expected, and why isn't this translating to higher operating margins and EPS?
A:Gross margins benefited from productivity improvements in manufacturing and pricing, despite ongoing tariff pressures. The company expects gross margins to remain around 63% for the year. However, operating margins and EPS are not seeing proportional increases due to other cost factors and investments.
Q:What is the company's outlook on the surgical market growth and its confidence in achieving the 3-4% growth guidance for the year?
A:The company remains confident in the 3-4% growth guidance, despite a softer Q1 surgical market due to weather and strikes. They see strong demand for cataract surgeries and expect market restructuring, such as increased use of office-based surgeries and hiring optometrists, to support growth.
Q:How is the company performing in the contact lens market, and what are the competitive dynamics?
A:The company is narrowing the gap with the market, gaining share in reusables and DAILIES internationally, though DAILIES in the U.S. are flat. They are confident in their ability to outgrow the market, driven by products like PRECISION7 and TOTAL 30, despite challenges in legacy business.
Q:What impact have Unity renewals had on monofocal IOL growth, and how is the company leveraging this?
A:Unity renewals have positively impacted monofocal IOL growth, with the company gaining share globally. Increased presence in operating rooms due to new products like CS machines has also contributed to growth.
Q:What needs to happen for the surgical cataract market to translate demand into higher growth, and what is the outlook for AT-IOL penetration in Europe?
A:To meet cataract demand, more OR time and efficiency improvements are needed, such as office-based surgeries and hiring optometrists. AT-IOL penetration in Europe is growing, with a 260 basis point increase in Q1, and is expected to continue catching up to the U.S. level of around 21%.
Q:What are the drivers of growth in the contact lens market, and how is the company performing geographically?
A:Growth drivers include price and mix shift to DAILIES, though international markets are showing resistance to price increases. The company is gaining share in reusables in the U.S. and DAILIES internationally, with a mixed performance across regions.
Q:How is the company addressing competitive pressure in the IOL market, and what is the outlook for new product launches?
A:The company is addressing competitive pressure with new products like PanOptix Pro, TruPlus, and Vivity 2.0. They expect these launches to stabilize and grow their market share, particularly in international markets.
Q:What is the company's outlook for growth in 2023, and how are new products expected to contribute?
A:The company expects growth to accelerate in the second half of 2023, driven by new products like Unity, Tryptyr, PanOptix Pro, and OTC brands. These products are expected to offset softer market growth in the first half.
Q:What is the company's strategy for M&A, and how does it view recent deals?
A:The company focuses on single-product companies for M&A, typically in the $50-500 million range. They remain cautious about larger deals and are prioritizing innovation and strategic fit over size.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific timing and impact of competitive pressures in the IOL market, as well as the exact contribution of new products to growth. Additionally, there was limited clarity on the timeline for addressing surgical market constraints and the precise impact of macroeconomic factors like energy prices on margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
AMD
ASCRS
IFRS measure
IOL category
Medicare
PRECISION
President Investor
TruPlus
Unity CS
Unity VCS
activity health
addition
astigmatism
base
category launch
community
counter
coverage
device
engagement
focus
gain category
implant
life
modality
momentum
option
payer
peer
portfolio
position
prescriber
pressure tariff
program
quality
replacement
role
share gain
share point
solution
speed
support
upgrade
vision distance
workflow
ALC Transcript
Alcon Inc. (ALC) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call presents a mixed picture: positive revenue growth and product launches are offset by flat operating margins and tariff pressures. The Q&A highlights optimism in product growth, but challenges in margins and competitive pressures remain. The market strategy appears sound, but financial health concerns persist due to flat free cash flow and margin pressures. Shareholder returns are stable, with no significant changes. Overall, the sentiment is neutral, as positive elements are balanced by ongoing challenges and uncertainties.
Alcon Inc. (ALC) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary and Q&A section indicate positive sentiment overall. Strong product launches and business updates, such as Tryptyr and Unity, are expected to drive growth. While there are challenges in international markets like China, management is confident about their strategies. The guidance for 2026 suggests optimism, with potential outperformance from new products. Despite some uncertainties in the IOL market, the company's focus on innovation and expanding its portfolio supports a positive outlook. The stock is likely to see a positive movement in the next two weeks, given these factors.
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Alcon Inc. (ALC) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call presents a mixed outlook. While there is optimism about new products, market expansion, and margin improvements, there are significant challenges such as tariff impacts, competition, and cautious guidance. The Q&A highlights management's cautiousness and lack of specific guidance, which could limit positive sentiment. The overall sentiment is neutral, as positive factors are offset by uncertainties and competitive pressures.
ALC Slides
ALC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
